News from cti biopharma corp. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 25, 2021, 07:00 ET CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on Thursday, Mar. 4

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference...

Feb 24, 2021, 18:30 ET CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to three new...

Feb 10, 2021, 23:55 ET CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new...

Jan 28, 2021, 22:58 ET CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new...

Dec 08, 2020, 07:00 ET CTI BioPharma to Present at The JMP Securities Hematology Summit on Tuesday, Dec. 15

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00...

Dec 06, 2020, 12:30 ET CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting

CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in the prevention of...

Nov 30, 2020, 07:00 ET CTI BioPharma Announces Publication of Article Highlighting Pacritinib Data from the PAC203 Phase 2 Study in Myelofibrosis in Blood Advances

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances. The article, titled...

Nov 10, 2020, 16:05 ET CTI BioPharma Reports Third Quarter 2020 Financial Results

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2020. "This past...

Nov 04, 2020, 11:41 ET CTI BioPharma Announces Oral Presentation at the 62nd American Society of Hematology Meeting

CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host...

Nov 02, 2020, 16:05 ET CTI BioPharma to Report Third Quarter 2020 Financial Results on November 10, 2020

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on...

Oct 13, 2020, 07:00 ET CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug...

Sep 29, 2020, 16:05 ET CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that following a recent Pre-NDA meeting with the U.S. Food and Drug Administration ("FDA" or "the...

Aug 06, 2020, 16:05 ET CTI BioPharma Reports Second Quarter 2020 Financial Results

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2020. "This past quarter ...

Jun 01, 2020, 07:00 ET CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib...

May 28, 2020, 07:00 ET CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare ...

May 07, 2020, 16:05 ET CTI BioPharma Reports First Quarter 2020 Financial Results

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2020. "With a sufficient cash runway...

Apr 27, 2020, 07:00 ET CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with...

Apr 08, 2020, 07:00 ET CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Needham Healthcare...

Mar 12, 2020, 16:05 ET CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019. "In the latter...

Mar 06, 2020, 18:48 ET CTI BioPharma Announces Closing of Rights Offering

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the closing of its previously announced rights offering (the "Rights Offering"). At the closing,...

Feb 14, 2020, 07:00 ET CTI BioPharma Announces Commencement of Rights Offering

CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million...

Feb 03, 2020, 07:01 ET CTI BioPharma Announces Proposed Rights Offering

CTI BioPharma Corp. (Nasdaq: CTIC) today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of...

Feb 03, 2020, 07:00 ET CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that following a meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency"), CTI...

Dec 09, 2019, 10:30 ET CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology Meeting

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the presentation of data from the Company's pacritinib development program, including results from ...

Nov 06, 2019, 09:08 ET CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting

CTI BioPharma Corp. (Nasdaq: CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib...